NL8202626A - Derivaten van 9-(2-hydroxyethoxymethyl)guanine. - Google Patents
Derivaten van 9-(2-hydroxyethoxymethyl)guanine. Download PDFInfo
- Publication number
- NL8202626A NL8202626A NL8202626A NL8202626A NL8202626A NL 8202626 A NL8202626 A NL 8202626A NL 8202626 A NL8202626 A NL 8202626A NL 8202626 A NL8202626 A NL 8202626A NL 8202626 A NL8202626 A NL 8202626A
- Authority
- NL
- Netherlands
- Prior art keywords
- guanine
- amino acid
- hydroxyethoxymethyl
- sup
- esters
- Prior art date
Links
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical class N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- -1 Amino acid esters Chemical class 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 11
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000003889 eye drop Substances 0.000 claims description 7
- 229940012356 eye drops Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000005886 esterification reaction Methods 0.000 claims description 5
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- KETQLEJEYONGLG-UHFFFAOYSA-N 2-[2-hydroxyethoxy(methyl)amino]-3,7-dihydropurin-6-one Chemical compound N1C(N(OCCO)C)=NC(=O)C2=C1N=CN2 KETQLEJEYONGLG-UHFFFAOYSA-N 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- IBAOFQIOOBQLHE-UHFFFAOYSA-N 2-amino-3,9-dihydropurin-9-ium-6-one;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N=CN2 IBAOFQIOOBQLHE-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- SUHXTVABLHHRST-UHFFFAOYSA-N 2-azidoacetyl chloride Chemical compound ClC(=O)CN=[N+]=[N-] SUHXTVABLHHRST-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000005100 Herpetic Keratitis Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- LOOICXPOOTTXRR-UHFFFAOYSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl 2-aminoacetate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)CN)C=N2 LOOICXPOOTTXRR-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 101100515516 Arabidopsis thaliana XI-H gene Proteins 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000006364 carbonyl oxy methylene group Chemical group [H]C([H])([*:2])OC([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- TYRGLVWXHJRKMT-QMMMGPOBSA-N n-benzyloxycarbonyl-l-serine-betalactone Chemical compound OC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-QMMMGPOBSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8202626A NL8202626A (nl) | 1982-06-29 | 1982-06-29 | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
| US06/507,712 US4548819A (en) | 1982-06-29 | 1983-06-23 | Derivatives of 9-(2-hydroxyethoxymethyl) guanine |
| HU832337A HU189709B (en) | 1982-06-29 | 1983-06-28 | Process for preparing ester derivatives of 9-/2-hydroxy-ethoxy-methyl/-guanine |
| CA000431347A CA1208637A (en) | 1982-06-29 | 1983-06-28 | Derivatives of 9-(2-hydroxyethoxymethyl)guanine |
| DE8383106299T DE3380410D1 (en) | 1982-06-29 | 1983-06-28 | Derivatives of 9-(2-hydroxyethoxymethyl)guanine |
| GB08317504A GB2122618B (en) | 1982-06-29 | 1983-06-28 | Purine derivatives |
| FI832355A FI76087C (fi) | 1982-06-29 | 1983-06-28 | Foerfarande foer framstaellning av terapeutiskt aktiva 9-(2-hydroxietoximetyl)guaninderivat. |
| JP58116807A JPS5910587A (ja) | 1982-06-29 | 1983-06-28 | グアニン誘導体 |
| DK297483A DK159444C (da) | 1982-06-29 | 1983-06-28 | Analogifremgangsmaade til fremstilling af derivater af 9-(2-hydroxyethoxymethyl)guanin |
| EP83106299A EP0099493B1 (en) | 1982-06-29 | 1983-06-28 | Derivatives of 9-(2-hydroxyethoxymethyl)guanine |
| IL69095A IL69095A (en) | 1982-06-29 | 1983-06-28 | 9-(2-hydroxyethoxymethyl)-guanine derivatives,their preparation and pharmaceutical compositions containing them |
| AT83106299T ATE45580T1 (de) | 1982-06-29 | 1983-06-28 | 9-(2-hydroxyethoxymethyl)guanin-derivate. |
| MYPI87002887A MY102248A (en) | 1982-06-29 | 1987-10-09 | Derivatives of 9-(2-hydroxyethoxymethyl) guanine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8202626 | 1982-06-29 | ||
| NL8202626A NL8202626A (nl) | 1982-06-29 | 1982-06-29 | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8202626A true NL8202626A (nl) | 1984-01-16 |
Family
ID=19839947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8202626A NL8202626A (nl) | 1982-06-29 | 1982-06-29 | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
Country Status (13)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8513460D0 (en) * | 1985-05-29 | 1985-07-03 | Glaxo Group Ltd | Chemical compounds |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| GB8725939D0 (en) * | 1987-11-05 | 1987-12-09 | Wellcome Found | Therapeutic compounds |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| IT1223604B (it) * | 1987-12-24 | 1990-09-29 | Co Pharma Corp Srl | Derivati purinici ad azione farmacologica |
| GB8800312D0 (en) * | 1988-01-07 | 1988-02-10 | Glaxo Group Ltd | Process |
| DE68922903T2 (de) * | 1988-12-19 | 1995-11-23 | Wellcome Found | Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. |
| GB8829571D0 (en) * | 1988-12-19 | 1989-02-08 | Wellcome Found | Antiviral compounds |
| GB8904855D0 (en) * | 1989-03-03 | 1989-04-12 | Beecham Group Plc | Pharmaceutical treatment |
| US5451799A (en) * | 1992-12-28 | 1995-09-19 | Matsushita Electric Industrial Co., Ltd. | MOS transistor for protection against electrostatic discharge |
| ES2157259T3 (es) * | 1993-06-10 | 2001-08-16 | Rolabo Sl | Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos. |
| GB9320316D0 (en) * | 1993-10-01 | 1993-11-17 | Smithkline Beecham Plc | Pharmaceuticals |
| TW282470B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1993-11-18 | 1996-08-01 | Ajinomoto Kk | |
| DE69513313T2 (de) * | 1994-02-01 | 2000-07-13 | Ajinomoto Co., Inc. | Verfahren zur Herstellung von Nukleinsäurebasenderivaten |
| US5994361A (en) * | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| US5840891A (en) * | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
| US5543414A (en) * | 1994-07-28 | 1996-08-06 | Syntex (Usa) Inc. | Achiral amino acid acyl esters of ganciclovir and its derivatives |
| PE32296A1 (es) * | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
| US6040446A (en) * | 1996-01-26 | 2000-03-21 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
| US5840890A (en) * | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| US5756736A (en) * | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| AU1543797A (en) * | 1996-01-26 | 1997-08-20 | F. Hoffmann-La Roche Ag | Process for preparing purine derivatives |
| US5700936A (en) * | 1996-01-26 | 1997-12-23 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate |
| US6703394B2 (en) | 1996-02-16 | 2004-03-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US5869493A (en) * | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
| ZA9810490B (en) * | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| CN100560073C (zh) | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | 用于治疗病毒感染的n4-酰基胞嘧啶核苷 |
| US20070293517A1 (en) * | 2004-06-09 | 2007-12-20 | Ramot At Tel Aviv University Ltd. | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety |
| US7846937B2 (en) * | 2005-05-25 | 2010-12-07 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
| CN115745997A (zh) * | 2022-11-30 | 2023-03-07 | 湖北省宏源药业科技股份有限公司 | 一种高纯度伐昔洛韦杂质h制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| AU515553B2 (en) * | 1976-03-01 | 1981-04-09 | The Wellcome Foundation Limited | Purine derivatives |
| JPS52105195A (en) * | 1976-03-01 | 1977-09-03 | Wellcome Found | Substituted purine |
| US4060616A (en) * | 1976-03-01 | 1977-11-29 | Burroughs Wellcome Co. | Purine derivatives with repeating unit |
-
1982
- 1982-06-29 NL NL8202626A patent/NL8202626A/nl not_active Application Discontinuation
-
1983
- 1983-06-23 US US06/507,712 patent/US4548819A/en not_active Expired - Lifetime
- 1983-06-28 AT AT83106299T patent/ATE45580T1/de not_active IP Right Cessation
- 1983-06-28 CA CA000431347A patent/CA1208637A/en not_active Expired
- 1983-06-28 DE DE8383106299T patent/DE3380410D1/de not_active Expired
- 1983-06-28 FI FI832355A patent/FI76087C/fi not_active IP Right Cessation
- 1983-06-28 GB GB08317504A patent/GB2122618B/en not_active Expired
- 1983-06-28 DK DK297483A patent/DK159444C/da not_active IP Right Cessation
- 1983-06-28 IL IL69095A patent/IL69095A/xx not_active IP Right Cessation
- 1983-06-28 EP EP83106299A patent/EP0099493B1/en not_active Expired
- 1983-06-28 JP JP58116807A patent/JPS5910587A/ja active Granted
- 1983-06-28 HU HU832337A patent/HU189709B/hu unknown
-
1987
- 1987-10-09 MY MYPI87002887A patent/MY102248A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US4548819A (en) | 1985-10-22 |
| DK297483D0 (da) | 1983-06-28 |
| DK297483A (da) | 1983-12-30 |
| DE3380410D1 (en) | 1989-09-21 |
| ATE45580T1 (de) | 1989-09-15 |
| FI76087B (fi) | 1988-05-31 |
| JPS5910587A (ja) | 1984-01-20 |
| JPH04990B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-01-09 |
| FI832355L (fi) | 1983-12-30 |
| DK159444B (da) | 1990-10-15 |
| EP0099493B1 (en) | 1989-08-16 |
| HU189709B (en) | 1986-07-28 |
| IL69095A0 (en) | 1983-10-31 |
| MY102248A (en) | 1992-05-15 |
| CA1208637A (en) | 1986-07-29 |
| GB2122618A (en) | 1984-01-18 |
| FI832355A0 (fi) | 1983-06-28 |
| DK159444C (da) | 1991-03-18 |
| GB2122618B (en) | 1985-11-13 |
| FI76087C (fi) | 1988-09-09 |
| IL69095A (en) | 1985-11-29 |
| EP0099493A1 (en) | 1984-02-01 |
| GB8317504D0 (en) | 1983-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8202626A (nl) | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. | |
| CN109422752B (zh) | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 | |
| SU1528316A3 (ru) | Способ получени производных дистамицина А или их гидрохлоридов | |
| FI93217C (fi) | Menetelmä terapeuttisesti aktiivisten nukleosidijohdannaisten estereiden ja amidien valmistamiseksi | |
| US5137918A (en) | N-(2'-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them | |
| EP3233889B1 (en) | Antimicrobial polymyxins for treatment of bacterial infections | |
| CA3137091A1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
| EP4086268A1 (en) | Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof | |
| US6806266B1 (en) | Staurosporin derivatives | |
| EP3838901B1 (en) | Compound for treatment of rabies and method for treatment of rabies | |
| CN108947912B (zh) | 一种靶向Neddylation通路的抗肿瘤化合物 | |
| EP4240422A1 (en) | Compounds and methods for modulating cdk9 activity | |
| FR2528048A1 (fr) | Amidines de la famille des mitosanes et leur application pharmacologique | |
| BG61729B1 (bg) | 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они | |
| Soltanzadeh et al. | Unexpected formation of 5-alkylidene derivatives of hydantoin from the Michael addition of 4-phenylurazole to fumaric esters | |
| EP3388430A1 (en) | Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound | |
| CN115073518B (zh) | 磷酸双依达拉奉酯类化合物、及其制备方法和用途 | |
| US20250019374A1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| Danyliuk et al. | Visible-light-induced photocatalytic iododi (per) fluoroalkylation of 5-amino-N-allyl-1, 2, 3-triazole-4-carboxamides | |
| US3029239A (en) | Basic substituted 1-and 7-alkylxanthines or salts thereof | |
| GB1603127A (en) | Rifamycin compounds | |
| EP1438320A1 (fr) | Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| FI60710C (fi) | Analogifoerfarande foer framstaellning av 9-(2-acyloxietoximetyl)purinfoereningar anvaendbara saosom antivirala medel | |
| EP3587416A1 (en) | 2-oxopiperidin-3-yl derivatives and use thereof | |
| JPH0417195B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |